La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Clarity Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG Clarity Pharmaceuticals' est Colin Biggin, nommé en Oct2019, a un mandat de 4.83 ans. La rémunération annuelle totale est A$ 929.70K, composée du salaire de 47.8% et des bonus 52.2%, y compris les actions et options de la société. détient directement 1.03% des actions de la société, d'une valeur de A$ 20.57M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.8 ans et 4.6 ans.

Informations clés

Colin Biggin

Directeur général

AU$929.7k

Rémunération totale

Pourcentage du salaire du PDG	47.8%
Durée du mandat du directeur général	4.8yrs
Propriété du PDG	1.0%
Durée moyenne d'occupation des postes de direction	4.8yrs
Durée moyenne du mandat des membres du conseil d'administration	4.6yrs

Mises à jour récentes de la gestion

Recent updates

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13

Analyse de la rémunération des PDG

Comment la rémunération de Colin Biggin a-t-elle évolué par rapport aux bénéfices de Clarity Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	n/a	n/a	-AU$31m
Sep 30 2023	n/a	n/a	-AU$28m
Jun 30 2023	AU$930k	AU$444k	-AU$25m
Mar 31 2023	n/a	n/a	-AU$23m
Dec 31 2022	n/a	n/a	-AU$21m
Sep 30 2022	n/a	n/a	-AU$23m
Jun 30 2022	AU$811k	AU$347k	-AU$24m
Mar 31 2022	n/a	n/a	-AU$21m
Dec 31 2021	n/a	n/a	-AU$19m
Sep 30 2021	n/a	n/a	-AU$15m
Jun 30 2021	AU$907k	AU$308k	-AU$10m
Mar 31 2021	n/a	n/a	-AU$9m
Dec 31 2020	n/a	n/a	-AU$9m
Sep 30 2020	n/a	n/a	-AU$8m
Jun 30 2020	AU$657k	AU$303k	-AU$7m

Rémunération vs marché: La rémunération totale de Colin ($USD 626.19K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 1.41M ).

Rémunération et revenus: La rémunération de Colin a augmenté alors que l'entreprise n'est pas rentable.

PDG

Colin Biggin

4.8yrs

Titularisation

AU$929,701

Compensation

Dr. Colin David Biggin, Ph D., has been Managing Director, Chief Executive Officer and Executive Director at Clarity Pharmaceuticals Ltd since October 1, 2019. Dr. Biggin joined Clarity Pharmaceuticals Pty...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Alan Taylor	Executive Chairman	10.8yrs	AU$1.13m	4.63% A$ 100.7m
Colin Biggin	MD, CEO & Executive Director	4.8yrs	AU$929.70k	1.03% A$ 22.4m
David Green	Chief Financial Officer	2.3yrs	AU$265.49k	pas de données
Shaemus Gleason	Executive Vice President of Operations	no data	pas de données	pas de données
Matthew Harris	Chief Scientific Officer	no data	AU$241.43k	1.92% A$ 41.8m
Lisa Sadetskaya	Director of Corporate Communications.	no data	pas de données	pas de données
Mary Bennett	Head of Human Resource	no data	pas de données	pas de données
Michelle Parker	Chief Clinical Officer	no data	pas de données	pas de données
Othon Gervasio	Chief Medical Officer	no data	pas de données	pas de données
Robert Vickery	Company Secretary	no data	AU$268.69k	pas de données

4.8yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de CU6 est considérée comme expérimentée (ancienneté moyenne 4.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Alan Taylor	Executive Chairman	10.8yrs	AU$1.13m	4.63% A$ 100.7m
Colin Biggin	MD, CEO & Executive Director	4.8yrs	AU$929.70k	1.03% A$ 22.4m
Christopher Roberts	Non-Executive Director	8.4yrs	AU$81.75k	5.68% A$ 123.4m
Thomas Ramdahl	Non-Executive Director	5.4yrs	AU$81.75k	0.16% A$ 3.6m
Robert Thomas	Lead Independent Director	3yrs	AU$79.56k	0.37% A$ 8.1m
Neal Shore	Member of Scientific Advisory Board	2.3yrs	pas de données	pas de données
Rosanne Robinson	Independent Non-Executive Director	13.8yrs	AU$90.59k	pas de données
Jason Lewis	Member of Scientific Advisory Board	no data	pas de données	pas de données
Oliver Sartor	Member of Scientific Advisory Board	4.4yrs	pas de données	pas de données
Paul Donnelly	Member of Scientific Advisory Board	no data	pas de données	pas de données
Andrei Iagaru	Member of Scientific Advisory Board	2.3yrs	pas de données	pas de données
Louise Emmett	Member of Scientific Advisory Board	2.2yrs	pas de données	pas de données

4.6yrs

Durée moyenne de l'emploi

70yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CU6 sont considérés comme expérimentés (ancienneté moyenne 4.6 ans).

Clarity Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

MD, CEO & Executive Director exercised options to buy AU$5.6m worth of stock.

Executive Chairman exercised options to buy AU$3.4m worth of stock.

Non-Executive Director exercised options to buy AU$1.1m worth of stock.

Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 23, 2023

MD, CEO & Executive Director exercised options to buy AU$493k worth of stock.

Recent updates

Clarity Pharmaceuticals Ltd Receives FDA Fast Track Designation for 64Cu-Sar-Bispsma

MD, CEO & Executive Director exercised options to buy AU$5.6m worth of stock.

No longer forecast to breakeven

Executive Chairman exercised options to buy AU$3.4m worth of stock.

No longer forecast to breakeven

No longer forecast to breakeven

Price target increased by 14% to AU$3.87

New minor risk - Shareholder dilution

Clarity Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Clarity Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Non-Executive Director exercised options to buy AU$1.1m worth of stock.

Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial

Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range

New major risk - Financial position

Price target increased by 13% to AU$2.48

Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA

Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level

Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer

No longer forecast to breakeven

Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE

Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial

Clarity Pharmaceuticals and PSI CRO AG Kick Off SAR-BispsMA Phase III

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 23, 2023

Clarity Pharmaceuticals Announces the Dosing of the First Patient in Its Theranostic (64) Cu Sar-Bombesin Phase I/Ii Trial in Metastatic Castrate Resistant Prostate Cancer Trial in Metastatic Castrates Resistant Prostate Cancer (Mcrpc)

Price target increased by 8.5% to AU$1.82

New major risk - Revenue and earnings growth

Clarity Pharmaceuticals Announces Successful Completion of Cohort 2 and Advancement to Cohort 2 of Theranostic Trial, Secure

Clarity Pharmaceuticals Announces Phase II US-Based Diagnostic Cu SAR-Bombesin

New minor risk - Profitability

MD, CEO & Executive Director exercised options to buy AU$493k worth of stock.

Clarity Pharmaceuticals Announces Positive Guidance from US FDA on Cu-64 Sar-Bispsma Phase III Trial in Prostate Cancer

Consensus EPS estimates fall by 13%

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Consensus revenue estimates increase by 261%

MD, CEO & Executive Director exercised options to buy AU$243k worth of stock.

Clarity Pharmaceuticals Ltd Announces Its Phase II Diagnostic 64 Cu Sartate Trial (Disco NCT04438304)

Clarity Pharmaceuticals Announces PROPELLER Trial Results - SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer

Clarity Pharmaceuticals Ltd Announces Diagnostic Prostate Cancer Trial Reaches Recruitment Target

Clarity Pharmaceuticals Ltd Announces Board Changes

Clarity Pharmaceuticals Ltd Announces Positive Topline Results from SAR-bisPSMA Diagnostic Trial

Price target increased to AU$1.54

Clarity Pharmaceuticals Announces IND Approval from the FDA for Theranostic Sar-Bombesin Trial in Prostate Cancer

Less than half of directors are independent

Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Phase II BOP Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Announces First Patient Treated in Therapeutic Prostate Cancer Trial

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 24, 2022

Consensus forecasts updated

Clarity Pharmaceuticals Ltd Successfully Imaged Its First Participants in the Diagnostic 64 CU SAR-Bombesin Trial (Bop) for Patients with PSMA-Negative Prostate Cancer in Australia

Clarity Pharmaceuticals Appoints Jeffrey Norenberg as Chief Scientific Officer

Clarity Strengthens Protection of the SAR-bisPSMA Product with Granting of China Patent

Clarity Pharmaceuticals Announces Recruitment Opens for Phase II Trial in Prostate Cancer

Consensus revenue estimates increase by 182%

Forecast to breakeven in 2025

Clarity Pharmaceuticals Ltd Advances to Cohort 3 of the Cl04 Trial of Sartate in Paediatric Neuroblastoma

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Clarity Pharmaceuticals Announces Diagnostic 64 Cu SAR-Bombesin Trial (BOP) for Patients with Prostate Cancer Is Open for Recruitment in Australia

Clarity Pharmaceuticals Announces Recruitment Complete for Diagnostic Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Appoints Louise Emmett to Its Scientific Advisory Board

Non-Executive Director recently bought AU$53k worth of stock

Clarity Pharmaceuticals Announces the Appointment of Rob Thomas, Non-Executive Director, to the Role of Lead Independent Director

Clarity Pharmaceuticals Announces IND Approval by US FDA for Phase II SAR-Bombesin trial

Non-Executive Director recently bought AU$58k worth of stock

Neal Shore Joins Clarity Pharmaceuticals Ltd.'s Clinical Advisory Board

Less than half of directors are independent

Clarity Pharmaceuticals Ltd Announces Successfully Treats First Participant in the Diagnostic 64Cu SAR-bisPSMA trial

Clarity Pharmaceuticals Successfully Treated Its First Participant in the Diagnostic Us-Based 64 Cu SAR-bisPSMA Trial for Patients with Biochemical Recurrence (BCR) of Prostate Cancer